Company Overview of Janssen Pharmaceutica NV
Janssen Pharmaceutica NV discovers, develops, and produces medicines and therapeutic solutions for diabetes, hepatitis, HIV, cancer, arthritis, dementia, and mental disorders. It offers fluid, semi-solid, and injectable medicines; and researches on neurosciences, infectious diseases and vaccines, oncology, immunology, and cardiovascular and metabolic disorders. The company was formerly known as N.V. Laboratoria Pharmaceutica Dr.C. Janssen and changed its name to Janssen Pharmaceutica NV in February 1964. Janssen Pharmaceutica NV was founded in 1934 and is based in Beerse, Belgium with research centers in Europe and the United States. Janssen Pharmaceutica NV operates as a subsidiary of Johns...
Founded in 1934
Key Executives for Janssen Pharmaceutica NV
Managing Director for Benelux
Compensation as of Fiscal Year 2017.
Janssen Pharmaceutica NV Key Developments
GenomeDx Biosciences Announces Research Collaboration with Janssen Pharmaceuticals to Evaluate the Decipher® Classifier and Decipher GRID® for Drug Development
May 8 18
GenomeDx Biosciences announced a research collaboration with Janssen Pharmaceuticals. As part of the agreement, GenomeDx will test samples using its genome-wide expression assay from multiple Janssen prostate cancer clinical trials to examine the association of prognostic and predictive signatures available on the Decipher GRID® platform with clinical outcomes.
Janssen Pharmaceutica NV Presents at 11th Annual European Life Sciences CEO Forum & Exhibition, Feb-26-2018
Feb 7 18
Janssen Pharmaceutica NV Presents at 11th Annual European Life Sciences CEO Forum & Exhibition, Feb-26-2018 . Venue: Hilton Zurich Airport Hotel, Hohenbuehlstrasse 10, Opfikon-Glattbrugg 8152, Zurich, Switzerland. Speakers: Julian Bertschinger, VP Janssen R&D, Head Therapeutic Platform Innovation.
Janssen Pharmaceutica NV Announces Results of Pivotal Phase 3 AMBER Study
Oct 25 17
Janssen Pharmaceutica, NV announced that the pivotal Phase 3 AMBER study achieved its primary endpoint, which focused on virologic response rate, and demonstrated that the investigational single-tablet regimen (STR) containing darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg (D/C/F/TAF) was non-inferior to darunavir/cobicistat (D/C) plus emtricitabine and tenofovir disoproxil fumarate (F/TDF) in previously untreated human immunodeficiency virus type 1 (HIV-1) positive adults. The results will be presented on October 27 at the 16thEuropean AIDS Conference in Milan, Italy. AMBER is a Phase 3 randomized, double-blind, active-controlled, international, multi-center, non-inferiority study designed to assess the safety and efficacy of D/C/F/TAF versus the control in HIV-1 treatment-na negative patients. The control was comprised of two separate medications D/C plus F/TDF and patients were
randomly assigned (362 D/C/F/TAF; 363 control). The primary endpoint was non-inferiority of the STR versus the control regarding the proportion of patients that achieved viral suppression (viral load [VL] of less than 50 copies per mL at 48 weeks per FDA Snapshot analysis). Reaching suppression of viral load (or the amount of HIV virus in the blood) is a key treatment goal for people living with HIV. Overall, the AMBER study met the primary endpoint, and D/C/F/TAF demonstrated non-inferiority versus the control group at 48 weeks.
Similar Private Companies By Industry
Recent Private Companies Transactions